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ABSTRACT 
Objectives/Background 
Excessive daytime sleepiness (EDS) is a common disorder, which can manifest in isolation or 
in combination with other neurological or psychiatric disorders. We know relatively little 
about the mechanisms underlying the development of EDS and the clinical management of 
patients with EDS remains an unmet need. In this study, we hypothesised that thalamic 
dopaminergic function would be altered in subjects with EDS and we sought to investigate 
this by assessing [123I]FP-CIT Single Photon Emission Computed Tomography (SPECT) 
data, which is a molecular imaging marker of dopamine transporter (DAT). 
Patients/Methods 
We performed a case-control study using people registered as healthy subjects in the 
Parkinson’s Progression Markers Initiative database. We assessed and compared semi-
quantified identified [123I]FP-CIT-SPECT in two groups of 21 healthy subjects with and 
without EDS, who were matched for age, gender, age of diagnosis, years of education and 
disease duration.  
Results 
Our findings show increased thalamic DAT binding in people with EDS compared to 
matched healthy subjects without EDS. Higher thalamic DAT binding also correlated with 
worse EDS scores.  
Conclusion: 
Our findings provide evidence that increased dopaminergic function in the thalamus may 
mediate excessive daytime sleepiness in humans. 
Keywords: Excessive daytime sleepiness; [123I]FP-CIT; Thalamus; Dopamine 
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1.0 INTRODUCTION 
Excessive daytime sleepiness (EDS) is defined as the inability to stay awake and alert during 
major waking episodes of the day, resulting into unintended lapses into drowsiness or 
sleep[1]. EDS is now acknowledged to substantially impair quality of life and work 
productivity, imposing a significant public health burden[2]. It has been reported to be 
implicated in up to 50% of work-related accidents, approximately 16% of motor vehicle 
accidents and 25% of home-based accidents [3]. Though EDS has strongly been associated 
with a range of neurological and psychiatric diseases including Parkinson’s disease (PD), 
epilepsy and schizophrenia[4], its prevalence in the general population has been estimated to 
be as high as 18% [5]. Several risk factors have been found to contribute to EDS including 
obesity, depression and age[6]. Although EDS can commonly manifest secondary to 
nocturnal sleep abnormalities and poor sleep hygiene[7], it is not simply the consequence of 
sleep deprivation/disruption, hence potentially driven by distinct mechanisms[8].  
Several brain regions, including the thalamus, hypothalamus, locus coeruleus and dorsal 
raphe are known to participate in the initiation and maintenance of alertness and sleep, 
though it remains to be ascertained the mechanisms underlying the development of EDS. The 
thalamus, specifically, has considerable nonphotic influence on sleep and circadian 
rhythmicity. The low- and high- frequency spindles generated by the GABAergic inhibitory 
reticular thalamic interneurons play an active role in inducing, maintaining and advancing 
non-rapid eye movement (NREM) sleep towards deeper stages[9]. 
Several neurotransmitters have also been implicated in playing significant roles in sleep and 
alertness, including norepinephrine, hypocretin, serotonin, GABA, glutamate and histamine. 
However, considerable evidence has emphasised the key role of the dopaminergic system in 
the sleep-wake regulation. Wisor, Nishino [10] demonstrated that mice with deletion of the 
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dopamine transporter (DAT) gene have 20% more wakefulness compared to controls and are 
unable to respond to psychostimulant drugs such as modafinil or amphetamine, suggesting 
that DAT may regulate wakefulness. Nearly all PD patients endure sleep disturbances, 
strongly suggesting the involvement of a dopaminergic component in the development of 
EDS. Studies have identified varying levels of extracellular dopamine in the terminal regions 
of ventral tegmental area (VTA) dopaminergic neurons across the sleep-wake cycle, with 
elevated levels of dopamine during waking and REM sleep[11].     
The origin of the dopamine innervation in the thalamus is markedly diverse, including 
dopaminergic projections from the VTA, the hypothalamus, and lateral parabrachial nucleus 
(LPbN), highlighting the complex organisation of the thalamus in terms of DAT content, 
distribution, density and origin[12].  The thalamus is also innervated by wake-active 
dopaminergic neurons from the ventral periaqueductal gray (vPAG), which also project to 
integral components of the sleep-wake regulatory system such as the prefrontal cortex, the 
ventrolateral preoptic nucleus (VPLO), the hypothalamic orexin/hypocretin cells, the pontine 
laterodorsal tegmental nucleus cholinergic neurons and the basal forebrain cholinergic 
neurons[13].  
A strong correlation has been identified between DAT binding and daytime sleepiness in 
PD[14], as well as a correlation between dopamine D2/D3 receptor binding and sleep 
deprivation[15]. Studies have also demonstrated a loss of vPAG gray matter dopaminergic 
neurons in patients with Multiple Systems Atrophy (MSA) and dementia with Lewy bodies 
(DLB), potentially contributing to excessive daytime sleepiness [16], as well as the dose of 
dopaminergic treatment predicting EDS in MSA [17]. Taken together, these results support 
the hypothesis that dopaminergic dysfunction may be associated with daytime sleepiness.  
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Here we hypothesised that thalamic presynaptic dopaminergic function would be altered in 
patients with EDS and we sought to investigate this by assessing [123I]FP-CIT single photon 
emission computed tomography (SPECT) data, which is a molecular imaging marker of 
dopamine transporter (DAT). 
 
2.0 MATERIALS AND METHODS 
2.1 Standard Protocol Approvals, Registrations, and Patient Consents 
Clinical characteristics, imaging and CSF data was downloaded from the Parkinson’s 
Progression Markers Initiative (PPMI) website on 15th of July 2016. PPMI is a five-year 
observational, international, multi-centre study designed to provide insight into disease 
aetiology by identifying PD progression biomarkers (http://www.ppmi-info.org). This study 
is registered with ClinicalTrials.gov, number NCT01141023. Institutional review boards 
approved the study and written informed consent was obtained from all participants. The 
present study was written according to the STROBE guidelines 
We screened 189 people registered as healthy subjects in the  PPMI database. We included 
healthy subjects older than 30 years, with no significant neurological dysfunction and no 
first-degree family member with PD. All participants had a Montreal Cognitive Assessment 
(MoCA) score greater than 26 and Geriatric Depression Scale (GDS) score less than 5.  
EDS was defined according to the ESS. This widely used, validated, self-reported and self-
completed instrument consists of 8 items, rating from 0: normal to 3: severe, with a 
maximum score of 24; a higher score corresponding to a higher degree of EDS[18]. 
Consistent with other studies, an ESS score of 10 or higher was set as a cut-off for EDS.  
We identified 21 people with an ESS score of 10 or greater (≥10), satisfying the criteria for 
subjective EDS [18]. Using propensity scores [21], people with EDS were matched 1:1 for 
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age, gender, years of education and Rapid eye movement (REM) sleep behaviour disorder 
(RBD) Questionnaire scores with healthy subjects without EDS (Table 1). All 42 subjects 
studied here were non-demented, non-depressed and had no other neurological or psychiatric 
comorbidities. Depressive features and anxiety were assessed with the short version of the 
Geriatric Depression Scale (GDS)  [15-item][19] and the State Trait Anxiety Total Score 
(STAI )[20]. Global cognitive status was measured using MoCA [21]. The following 
cognitive assessments were also performed: Benton Judgement of Line Orientation (BJLO) 
[22], Hopkin’s Learning Verbal Test-revised (HVLT)[23], Semantic Fluency Test (SFT) [24] 
and Symbol Digit Modalities Test (SDMT) [25]. Autonomic dysfunction was assessed with 
Scale for Outcomes for Autonomic Function (SCOPA-AUT) [26]. Olfactory dysfunction was 
measured by the University of Pennsylvania Smell Identification Test (UPSIT)). All 42 
subjects enrolled in this study were non-demented, non-depressed and had no other 
neurological or psychiatric comorbidities. 
Table 1. Demographic characteristics of healthy subjects with and without excessive daytime 
sleepiness. 
 HS without EDS 
(n=21) 
HS with EDS 
(n=21) 
P value* 
Age at screening1 (mean ±SD) 53.86 ± 9.11 53.94 ± 11.71 0.980  
Gender male2, % (n) 81.0% (17) 74.4% (15) 0.474  
Year of Education2 (mean ± SD) 15.05 ± 2.54 14.48 ±2.77 0.279  
RBD Score2 (mean ± SD) 4.29 ± 3.27 4.38 ± 2.46 0.721  
*All P values are uncorrected (1t test and 2Mann-Whitney U tests).  
RBD: Rapid eye movement sleep behaviour disorder  
2.2 Dopaminergic imaging 
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SPECT images were obtained 4 ± 0.5 h after administrating an injection with approximately 
185 MBq [123I]FP-CIT, with a total scan duration of 30-45 minutes. Raw SPECT data was 
acquired into a 128 × 128 matrix stepping each 3º for a total of 120 (or 4º for a total of 90) 
projections in a window centred on 159 ±10% KeV. Raw SPECT data for all subjects was 
transferred back to the Institute for Neurodegenerative Disorders Core Imaging Lab for 
standardised reconstruction, attenuation correction and quantification. Briefly, reconstruction 
was carried out using an iterative OSEM algorithm implemented on a Hermes workstation 
and subsequent processing was performed using PMOD (PMOD Technologies). A Chang 0 
attenuation correction was applied using a site-specific mu empirically determined by the 
anthropomorphic brain phantom acquired at each site. A standard Gaussian 3D 6.0mm filter 
was applied to each image volume, followed by normalisation to standard MNI space.  All 
SPECT images were visually interpreted by two experienced, independent readers who were 
blinded to the subject’s clinical diagnosis.  
2.3 Region of Interest analysis 
For this study, normalised SPECT images were loaded together with a single subject MRI 
template in Montreal Neurological Institute (MNI) space using Analyze 11.0 software (Mayo 
Foundation). [123I]FP-CIT SBRs in the thalamus, striatum, substantia nigra, globus pallidus, 
raphe nuclei, and locus coeruleus was calculated using a region of interest (ROI) analysis, 
with the occipital cortex serving as the reference region. ROIs were manually delineated on 
the MRI template using Analyze 11.0, before being applied on the SPECT images. ROIs 
where then manually adjusted on the SPECT images to compensate for individual variations, 
without altering the size or shape of the template.  
The thalamus, caudate, putamen, globus pallidus and substantia nigra, were manually 
delineated using a reliable, repeatable and robust technique[27]. The raphe complex was 
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drawn according to the anatomical location of the rostral and caudal raphe nuclei, as depicted 
by Hornung [28]. Regional estimates of Specific Brain Regions  were calculated as the ratio 
of the mean ROI binding divided by the occipital cortex. This measure approximates the non-
displaceable binding potential (BPND), when the radioligand is in equilibrium at the target site 
and has previously been reported with Ioflupane SPECT[29]. 
2.4 Statistical methods 
Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, 
Illinois, USA) and GraphPad Prism (version 6.0c), respectively. For all variables, variance 
homogeneity and Gaussianity was tested with Kolmogorov-Smirnov test. Parametric (t-test) 
and non-parametric (Mann-Whitney U) test were used for between-group comparisons, as 
appropriate. Categorical variables were compared using a χ2 test. Univariate and multivariate 
linear regression analyses were performed to assess the main effects of clinical and imaging 
variables between healthy subjects with and without EDS, controlling for age and gender. 
Sensitivity analysis was performed to evaluate the effect of gender on clinical and imaging 
variables. All data are presented as mean ±SD, and the level α was set for all comparisons at 
P<0.05.  
 
3.0 RESULTS 
In this study, we performed a case-control study in 21 people with EDS versus 21 healthy 
subjects without EDS, comparing semi-quantified [123I]FP-CIT SPECT, neurobehavioural, 
neuropsychological, cognitive and autonomic features amongst the groups. There were no 
significant differences in neuropsychiatric, autonomic and cognitive assessments between the 
group of healthy subjects with and without EDS (all P>0.10; Table 2). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
Table 2. Clinical characteristics of healthy subjects with and without excessive daytime 
sleepiness. 
 HS without EDS 
(n=21) 
HS with EDS 
(n=21) 
P value 
SCOPA-AUT2 (mean ± SD) 5.81 ± 4.93 5.80 ± 3.40 0.703 
GDS2 (mean ±SD) 1.81 ± 2.14 0.81 ± 0.87 0.205 
STAI Total Score2 (mean ±SD) 63.76 ± 23.13 56.95 ± 10.42 0.330 
MoCA2 (mean ±SD) 28.52 ± 1.12 28.48 ± 1.17 0.897 
BJLO2 (mean ±SD) 12.76 ± 1.87 13.29 ± 2.26 0.146 
HVLT Total1 (mean ±SD) 36.81 ± 5.34 39.81 ± 5.61 0.045 
SFT Score1 (mean ±SD) 51.14 ± 12.16 55.19 ± 12.59 0.871 
SDMT Score1 (mean ±SD) 50.14 ± 12.31 50.00 ± 11.61 0.950 
UPSIT2 (mean ± SD) 33.81 ± 5.01 33.52 ± 4.65 0.930 
SCOPA-AUT: the scale for outcomes for PD-autonomic function; GDS: 15-item Geriatric Depression Scale, 
MoCA: Montreal Cognitive Assessment Scale; BJLO: Benton Judgement of Line Orientation; HVLT: Hopkins 
Verbal learning Test – revised; STAI: state and train anxiety scale. 
*All P values are uncorrected (1t test and 2Mann-Whitney U test). 
 
Thalamic [123I]FP-CIT specific binding ratios (SBRs) was significantly increased in people 
with EDS compared to healthy subjects without EDS (1.78 ±0.21 vs 1.64 ±0.18, P=0.026; 
Table 3, Figure 1). Linear regression analyses revealed that increased thalamic [123I]FP-CIT 
SBRs correlated with worse EDS scores (adjusted r2=0.128, P=0.012), which remained 
significant after adjusting for age (adjusted r2=0.106, P=0.013) and gender (adjusted 
r
2
=0.115, P=0.014) in people with EDS (Figure 1). No other associations were found 
between clinical and imaging data and EDS at the univariate level (all P>0.10).  
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Figure 1 Comparison between people with EDS and those without EDS (A) Bar column 
graph showing that people with EDS have significantly higher thalamus [123I]FP-CIT specific 
binding ratios (SBRs) than healthy subjects (P=0.026) (B) Thalamus [123I]FP-CIT SBRs were 
positively correlated with increased EDS using linear, logarithmic and inverse models 
(adjusted r2=0.128, P=0.012) in our cohort of healthy subjects. 
 
We then assessed DAT uptake values in other brain areas with known rich DAT density, 
including the striatum, substantia nigra and globus pallidus, but found no significant 
differences in [123I]FP-CIT uptake between people with and without EDS (P>0.10). [123I]FP-
CIT uptake in raphe nucleus and locus coeruleus has shown to provide indirect measures of 
serotonergic (serotonin transporter) and noradrenergic (noradrenergic transporter) system, 
respectively [29, 30]. We found no significant differences in raphe nucleus and locus 
coeruleus [123I]FP-CIT SBRs between healthy subjects with and without EDS (P>0.10; Table 
3).  
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Table 3. [123I]FP-CIT imaging of healthy subjects with and without excessive daytime 
sleepiness. 
 HS without 
EDS 
(n=21) 
HS with EDS 
(n=21) 
P Value* % change 
Striatum1 (mean ±SD) 3.49 ±0.58 3.71 ±0.66 0.270 +6.30 
Globus Pallidus1 (mean ±SD) 3.34 ±0.52 3.58 ±0.58 0.178 +7.19 
Substantia nigra2 (mean ±SD) 1.41 ± 0.25 1.40 ± 0.26 0.855  -0.71 
Thalamus1 (mean ±SD) 1.64 ±0.18 1.78 ±0.21 0.026 +8.54 
Rostral raphe nucleus1  1.40 ±0.17 1.35 ±0.18 0.321 -3.57 
Caudal raphe nucleus1  1.15 ±0.19 1.12 ±0.28 0.604 -2.61 
Locus coeruleus1 1.27 ±0.23 1.25 ±0.11 0.737 -1.57 
*P values are uncorrected (1t test and 2Mann-Whitney U tests,)  
 
 
We also explored the effect of gender on clinical and imaging variables within the whole 
cohort and found no significant differences in DAT uptake in any of the regions of interest, as 
well as clinical variables, between males and females.  
4.0 DISCUSSION  
Our findings demonstrate increased thalamic DAT uptake in people with EDS, which further 
correlates with the severity of EDS, suggesting that increased dopaminergic function may be 
associated with EDS in humans. By using non-invasive SPECT molecular imaging we found 
no other changes related to DAT in DAT-rich areas such as the striatum, substantia nigra or 
globus pallidus. [123I]FP-CIT SPECT of raphe nucleus and locus coeruleus provides indirect 
measures for the serotonin and noradrenergic transporters, respectively [31], however no 
uptake differences were found between people with EDS and healthy subjects without EDS. 
Moreover, no other associations were found between imaging and clinical data related to 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14 
neuropsychiatric, cognitive and autonomic function, suggesting that thalamic dopaminergic 
function may contribute to EDS development in humans. 
There is growing evidence that dopamine modulates wakefulness, exerting a wake-promoting 
action. Studies have demonstrated that drugs that enhance dopaminergic signalling, through 
DAT blockade or inducing dopamine release, increase wakefulness in humans [32]. In fact, 
antipsychotic drugs that block dopamine D2 receptors induce sedation in humans [33] and 
reduce wakefulness in rats [34]. Volkow, Wang [15] discovered a reduction in D2/D3 receptor 
binding within the thalamus and striatum after sleep deprivation, with the magnitude of this 
reduction correlating with sleepiness and fatigue. These findings indicate an association 
between increased dopamine release and sleep deprivation. Although reductions in DAT 
density are suggestive of loss of dopaminergic terminals, evidence has also suggested that an 
upregulation of DAT could be indicative of reduced synaptic dopamine levels. Radioligands 
including [123I]FP-CIT have been reported to compete with endogenous dopamine, hence 
leading to an overestimation of DAT availability.  Therefore, increased DAT could indicate a 
reduction of extracellular dopamine level in individuals with EDS [35].  Sossi, de la Fuente-
Fernandez [36] reported that greater DAT levels were directly associated with lower 
dopamine turnover and lower changes in synaptic dopamine concentration. Thus, an 
increased uptake of [123I]FP-CIT in the thalamus could be indicative of thalamic 
dopaminergic dysfunction in people with EDS.   
Studies have also demonstrated, however, that DAT has direct implication in sleep and 
wakefulness. Qu, Xu [37] demonstrated the wake-promoting effect of GBR12909, a 
dopamine transporter inhibitor, in a dose-dependent manner. Therefore, if a reduction or 
inhibition of DAT causes wakefulness, we could assume that an increase in DAT may induce 
sleepiness.   
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The cellular basis underlying sleep regulation is complex, with much remaining poorly 
understood. Though dopamine has been implicated in regulating the sleep-wake cycle, the 
underlying dopamine pathway responsible for this remains unknown. Gonzalez, Moreno-
Delgado [38] identified a potential mechanism for how dopamine can regulate the sleep/wake 
cycle via a circadian-controlled receptor heteromer. They described how the production of 
serotonin and melatonin by the pineal gland is modulated by a circadian-related 
heteromerization of adrenergic and dopaminergic D4 receptors, through which dopamine 
inhibits adrenergic receptor signalling, blocking the synthesis of melatonin[38]. 
Furthermore, dopamine-containing neurons primarily arising in the VTA and substantia nigra 
pars compacta are recognised to innervate areas involved in sleep/wake regulation including 
the serotonergic cells of the dorsal raphe nucleus and medial raphe nucleus, the orexinergic 
arousal system of the lateral hypothalamus, the noradrenergic cells of the locus coeruleus, the 
histaminergic neurons of the posterior hypothalamus and the cholinergic cells of the basal 
forebrain[39].  
DAT content of dopaminergic axons has been found to vary across the thalamus, suggesting 
that dopaminergic signalling is more temporally and spatially restricted in particular regions 
of the thalamus. Therefore, an overall increase in DAT binding may actually be an indication 
of alterations of dopamine in specific thalamic nuclei, potentially differing from those 
inducing arousal.  
Behavioural arousal is impaired in dopamine D1 receptor knockout mice, whereas systematic 
administration of selective dopamine D1 agonists increases wakefulness and reduces slow 
wave sleep and REM sleep. Furthermore, administration of dopamine D1 antagonist leads to 
sedation and reduces wakefulness, whereas slow wave sleep and REM sleep are augmented. 
Similar effects are observed when D2 receptors are targeted [40]. Notably, Kimmel, Joyce 
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[41] reported that D2 receptor agonists decreased the half-life of DAT, and D2 receptor 
antagonist increased the half-life of DAT, showing that dopamine receptors influence DAT 
kinetics.  These findings together not only demonstrate the unpredictable nature that varying 
dopamine concentration has on the sleep/wake cycle, but also highlight that dopamine 
transporters may play an imperative role in sleep regulation.  
Further, EDS has been found to be exacerbated by dopamine agonists in Parkinson’s disease 
patients and those suffering from restless legs syndrome. Specifically, Pramipexole, a 
dopamine agonist which is documented to increase sleepiness, exerts a potent agonistic effect 
on the D2 receptor family with preferential affinity towards D3 receptors [42]. The thalamus 
expresses a heterogeneous distribution of D2 and D3 receptors, as demonstrated by Rieck and 
colleagues in vivo by using positron emission tomography with radioligands [123I]Epideopride 
and [18F]fallypride [43]. It could, therefore, be possible that D2/D3 agonists’ mechanism of 
action is within the thalamus, causing sleepiness by reducing cAMP levels, thus, the global 
thalamic output to the cortex. However, the development of EDS in Parkinson’s disease may 
be a more complex phenomenon that might involve a profound loss of D3 receptors, 
independent of the treatment use [44].   
It is important to consider that the subjective nature of the ESS means that it can often be 
misjudged as fatigue or lassitude, thus not only presenting a diagnostic challenge, but it also 
hinders the ability to determine the physiology of daytime sleepiness. Patients and clinicians 
often use other terms such as ‘fatigue’ or ‘tiredness’ interchangeably, thus leading to 
semantic confusion. However, despite some overlap, EDS and fatigue have different features 
[45]. It would, therefore, be both useful  and informative if we had additional comparisons 
with the Multiple Sleep Latency Test (MSLT). This test is considered the gold-standard for 
objective assessment of sleepiness by the American Academy of Sleep Medicine [46], with 
advantages including measuring the functional consequences of sleepiness at two hour 
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intervals across the waking portion of the day and being scientifically validated to effectively 
detect varying degrees of sleepiness. Thus, this additional data could provide additional 
insight into the pathophysiology of sleepiness. It is notable,  however, that in light of recent 
observation,  the robust status of MSLT diagnosing EDS and narcolepsy has been questioned.  
Johns [47] reported that the MSLT was the least accurate measure of daytime sleepiness 
compared to ESS and Maintenance of Wakefulness Test (MWT), with ESS posing as the 
most accurate assessment of EDS. Further, Goldbart and colleagues concluded that the MSLT 
was had  a large number of false positive results [48].  
It is also imperative to recognise that EDS has a multifactorial aetiology. Although our cohort 
did not report any sleep-specific comorbidities and were matched for RBDQ scores, it does 
not exclude the possibility of these subjects experiencing an unreported underlying sleep 
disorder such as sleep apnoea or restless legs syndrome, as well as mood disorders or side 
effects of medication. Therefore, although increased DAT uptake in the thalamus appears to 
be associated with EDS, it may be causally associated with other potential sleep disorders, 
which are inevitably reported to cause daytime sleepiness. Furthermore, Koch and colleagues 
demonstrated gender-specific differences in DAT uptake within the thalamus. Specifically, 
females were reported to have 31% higher DAT uptake within the thalamus compared to 
males [49]. Although the EDS cohort only encompassed an additional two females compared 
to the cohort without EDS, we took this notion into consideration and explored the potential 
effect of gender on DAT uptake. We did not find an association between gender and DAT 
uptake in any of the regions of interest, as well as gender having no effect on the association 
between thalamic DAT uptake and daytime sleepiness.  
Furthermore, the complexity of EDS means that neither the sleep-state nor wakefulness can 
solely be explained by the action of a single site,  but is presumed to arise as a result of the 
intimate interplay between many regions and distributed systems, including the orexinergic 
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neurons in the hypothalamus [50], cholinergic neurons in the basal forebrain and 
serotoninergic neurons in the raphe [51]. It would, therefore, be interesting to determine how 
the dopaminergic system interacts with non-dopaminergic systems to induce EDS. [123I]FP-
CIT is not specific for serotonin or noradrenaline, hence may need future Positon Emission 
Tomography (PET) scan to elucidate our results further. It is also possible that people with 
EDS share a common increase in thalamic [123I]FP-CIT binding, but their underlying EDS 
aetiology may vary substantially. Sleep is a structured process, with the sleep-wake cycle 
being governed by a complex, multilevel neuronal system in the brain stem, thalamus, 
hypothalamus and basal forebrain [52]. A disruption in any of these regions could potentially 
cause EDS, which could vary from individual to individual. Additionally, we included 
subjects with a pathological increase of ESS score. Though the ESS is widely used and 
recommended for screening for EDS, the subjective nature of the instrument inevitably 
introduces bias according to the subject’s motivation, fatigue or recall.  
Understanding the pathophysiology of EDS, including determining which systems are 
involved in this specific phenomenon, will not only heighten our understanding of sleep, but 
will encourage the development of therapies, with reduced side-effects, to tackle this 
symptom in the general public, as well as multicentric diseases such as PD. A variety of 
sleep-waking agents, including modafinil and methylphenidate are recognised to induce 
wakefulness via the dopaminergic system. Therefore, increasing our knowledge surrounding 
the mechanisms underlying sleepiness will allow selectivity for these effects, as well as 
tailoring these treatments based on the patient’s neurophysiological alterations. Dopaminergic 
function, specifically DAT, should be further investigated to confirm its role in regulating the 
sleep-wake cycle.  
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• People with excessive daytime sleepiness exhibit higher thalamic [
123
I]FP-CIT uptake  
• The severity of sleepiness correlates with increased thalamic [
123
I]FP-CIT uptake 
• Age or gender does not affect this association  
 
